Literature DB >> 15168377

Non-enteropathic hemolytic uremic syndrome: causes and short-term course.

Alex R Constantinescu1, Martin Bitzan, Lynne S Weiss, Erica Christen, Bernard S Kaplan, Avital Cnaan, Howard Trachtman.   

Abstract

BACKGROUND: Nondiarrheal or Streptococcus pneumoniae-related hemolytic uremic syndrome (HUS) represents a heterogeneous group of disorders. This study was performed to: (1) describe the current incidence, causes, demographic features, hospital courses, and short-term outcomes of non-enteropathic HUS; (2) compare findings in patients with non-enteropathic HUS with those obtained from a contemporaneous cohort of children with enteropathic or diarrhea-associated HUS (D+ HUS) diagnosed and treated at the same clinical sites; and (3) identify clinical or laboratory features that differentiate these 2 groups and predict disease severity and the short-term outcome in patients with non-enteropathic HUS.
METHODS: Data were collected from patients screened between 1997 and 2001 for enrollment in a multicenter trial of SYNSORB Pk (SYNSORB Biotech Inc, Calgary, Alberta, Canada) in D+ HUS, but who were ineligible because of lack of a diarrhea prodrome. The following features were recorded: age; sex; ethnicity; prodromal symptoms; cause; nadir values for hemoglobin, hematocrit, and platelet count; use of dialysis; and length of hospitalization.
RESULTS: Twenty-seven of 247 children with HUS had non-enteropathic HUS (11%). Twenty-four patients (15 boys, 9 girls), whose medical records were complete and available for review, comprise the study cohort. Mean age at onset was 4.2 +/- 0.9 (SE) years. Infection caused by S pneumoniae was diagnosed in 9 patients (38%). Dialysis was performed in 17 patients (71%) for 40 +/- 27 days. Median length of hospitalization was 22 days (range, 2 to 71 days). Children with S pneumoniae-related HUS had a longer hospital stay than those with other causes of non-enteropathic HUS, but all patients with S pneumoniae-related HUS recovered kidney function. Dialysis therapy was required more often (17 of 24 versus 59 of 145 children; P = 0.025) and hospital stays were longer (median, 22 versus 9 days; P = 0.002) in children with non-enteropathic HUS compared with patients with D+ HUS who were enrolled in the SYNSORB Pk clinical trial.
CONCLUSION: (1) The incidence of non-enteropathic HUS is approximately one tenth that of D+ HUS; (2) patients with non-enteropathic HUS require dialysis therapy more often and are hospitalized more than twice as long during the acute episode compared with those with D+ HUS; (3) infection caused by S pneumoniae accounts for nearly 40% of cases of non-enteropathic HUS; and (4) although S pneumoniae-related HUS is associated with a less favorable short-term course than other types of non-enteropathic HUS or D+ HUS, the long-term prognosis for recovery of renal function appears to be good in these patients.

Entities:  

Mesh:

Year:  2004        PMID: 15168377     DOI: 10.1053/j.ajkd.2004.02.010

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  66 in total

1.  Atypical hemolytic uremic syndrome associated with H1N1 influenza A virus infection.

Authors:  Howard Trachtman; Christine Sethna; Robyn Epstein; Marise D'Souza; Lorry G Rubin; Christine C Ginocchio
Journal:  Pediatr Nephrol       Date:  2010-08-30       Impact factor: 3.714

2.  Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.

Authors:  Olga Nikolajeva; Austen Worth; Rosie Hague; Nuria Martinez-Alier; Joanne Smart; Stuart Adams; E Graham Davies; H Bobby Gaspar
Journal:  J Clin Immunol       Date:  2015-04-15       Impact factor: 8.317

3.  Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome.

Authors:  Fengxiao Bu; Tara Maga; Nicole C Meyer; Kai Wang; Christie P Thomas; Carla M Nester; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2013-09-12       Impact factor: 10.121

4.  Exposure of Thomsen-Friedenreich antigen in Streptococcus pneumoniae infection is dependent on pneumococcal neuraminidase A.

Authors:  Mamie T Coats; Trudy Murphy; James C Paton; Barry Gray; David E Briles
Journal:  Microb Pathog       Date:  2011-03-04       Impact factor: 3.738

5.  Renal failure, respiratory distress, and an atypical purpuric rash in a full-term infant with omphalocele and hypospadias: Answers.

Authors:  Aaron J Weiss; Kenny Kronforst
Journal:  Pediatr Nephrol       Date:  2019-06-24       Impact factor: 3.714

6.  Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

Authors:  Marina Noris; Jessica Caprioli; Elena Bresin; Chiara Mossali; Gaia Pianetti; Sara Gamba; Erica Daina; Chiara Fenili; Federica Castelletti; Annalisa Sorosina; Rossella Piras; Roberta Donadelli; Ramona Maranta; Irene van der Meer; Edward M Conway; Peter F Zipfel; Timothy H Goodship; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

Review 7.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

8.  Characteristics and outcome of hemolytic uremic syndrome in Sudanese children in a single Centre in Khartoum State.

Authors:  Eltigani Mohamed Ahmed Ali; Nagmelddin Mohamed Abbakar; Mohamed Babikir Abdel Raheem; Rashid Abdelrahman Ellidir
Journal:  Sudan J Paediatr       Date:  2017

9.  Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.

Authors:  Johannes Hofer; Andreas R Janecke; L B Zimmerhackl; Magdalena Riedl; Alejandra Rosales; Thomas Giner; Gerard Cortina; Carola J Haindl; Barbara Petzelberger; Miriam Pawlik; Verena Jeller; Udo Vester; Bettina Gadner; Michael van Husen; Michael L Moritz; Reinhard Würzner; Therese Jungraithmayr
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 8.237

Review 10.  Advances and challenges in the management of complement-mediated thrombotic microangiopathies.

Authors:  Jean-Claude Davin; Nicole C A J van de Kar
Journal:  Ther Adv Hematol       Date:  2015-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.